Benign Prostatic Hyperplasia Antibody (YBPH-1): sc-69649
- Benign Prostatic Hyperplasia Antibody (YBPH-1) is a mouse monoclonal IgM Benign Prostatic Hyperplasia antibody provided at 100 µg/ml
- raised against highly purified Benign Prostatic Hyperplasia of human origin
- recommended for detection of Benign Prostatic Hyperplasia of human origin by IF and IHC(P); may cross-react with human prostate epithelial cells
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Benign Prostatic Hyperplasia Antibody (YBPH-1). This work is in progress.
QUICK LINKS
SEE ALSO...
Benign Prostatic Hyperplasia Antibody (YBPH-1) is a mouse monoclonal IgM antibody that detects the Benign Prostatic Hyperplasia protein (BPH) of human origin by immunofluorescence (IF) and immunohistochemistry. Anti-BPH antibody (YBPH-1) is available as the non-conjugated format. BPH is characterized by an increase in prostate size due to the formation of large nodules in the periurethral region, which can lead to various complications such as urinary obstruction and increased risk of urinary tract infections. BPH protein plays a crucial role in regulating cell growth and differentiation within the prostate, and dysregulation can contribute to BPH pathophysiology. Understanding BPH protein structure provides insights into how alterations may lead to BPH development and associated symptoms. Anti-BPH antibody (YBPH-1) detection capabilities in tissue samples help researchers and clinicians better understand BPH mechanisms, paving the way for more effective treatments and interventions. With specificity for human tissues, BPH monoclonal antibody (YBPH-1) serves as an essential tool for both diagnostic and research applications in urology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Benign Prostatic Hyperplasia Antibody (YBPH-1) References:
- Prostate stem cells and benign prostatic hyperplasia. | Isaacs, JT. 2008. Prostate. 68: 1025-34. PMID: 18386293
- Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. | Dedhia, RC. and McVary, KT. 2008. J Urol. 179: 2119-25. PMID: 18423748
- Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. | Emberton, M., et al. 2008. Int J Clin Pract. 62: 1076-86. PMID: 18479366
- Risk factors for benign prostatic hyperplasia. | Jacobsen, SJ. 2007. Curr Urol Rep. 8: 281-8. PMID: 18519012
- Diagnosis and management of benign prostatic hyperplasia. | Edwards, JL. 2008. Am Fam Physician. 77: 1403-10. PMID: 18533373
- Treatment options for benign prostatic hyperplasia in older men. | Miano, R., et al. 2008. Med Sci Monit. 14: RA94-102. PMID: 18591930
- The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia. | Lepor, H., et al. 2008. Rev Urol. 10: 85-91. PMID: 18660858
- Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. | Hoke, GP. and McWilliams, GW. 2008. Am J Med. 121: S3-10. PMID: 18675615
- Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. | Rittmaster, R., et al. 2008. Urology. 72: 808-12. PMID: 18718641
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Benign Prostatic Hyperplasia Antibody (YBPH-1) | sc-69649 | 100 µg/ml | $322.00 |